Search companies

Live

Tuesday, 17 November 2026 · 578 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

NeuroScientific Biopharmaceuticals becomes Miro Sciences as it prepares for planned phase 2 trial

MSX: $0.054 +0.00% · MC: $16M

The company’s name change to Miro Sciences Ltd and ticker change from NSB to MSX took effect after shareholder approval and formal registration. The company says the new identity reflects its focus on its StemSmart cell therapy platform and preparations for a planned phase 2 trial in Australia and the United States for potential treatments for refractory Crohn’s disease.

Source announcements: 2026-10-28 09:17 to 2026-10-28 09:17 Sydney time
Story updated 2026-10-28 10:27 Sydney time
SourcesName Change to Miro Sciences (MSX)
Comments